BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23370364)

  • 1. A phase I study of pomalidomide (CC-4047) in combination with cisplatin and etoposide in patients with extensive-stage small-cell lung cancer.
    Ellis PM; Jungnelius U; Zhang J; Fandi A; Beck R; Shepherd FA
    J Thorac Oncol; 2013 Apr; 8(4):423-8. PubMed ID: 23370364
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.
    Goldman JW; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Garassino MC; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Każarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Thiyagarajah P; Jiang H; Paz-Ares L;
    Lancet Oncol; 2021 Jan; 22(1):51-65. PubMed ID: 33285097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. NCIC CTG IND.190 phase I trial of dalotuzumab (MK-0646) in combination with cisplatin and etoposide in extensive-stage small-cell lung cancer.
    Ellis PM; Shepherd FA; Laurie SA; Goss GD; Olivo M; Powers J; Seymour L; Bradbury PA
    J Thorac Oncol; 2014 Mar; 9(3):410-3. PubMed ID: 24518092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I trial of the Hedgehog inhibitor, sonidegib (LDE225), in combination with etoposide and cisplatin for the initial treatment of extensive stage small cell lung cancer.
    Pietanza MC; Litvak AM; Varghese AM; Krug LM; Fleisher M; Teitcher JB; Holodny AI; Sima CS; Woo KM; Ng KK; Won HH; Berger MF; Kris MG; Rudin CM
    Lung Cancer; 2016 Sep; 99():23-30. PubMed ID: 27565909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial.
    Goto K; Ohe Y; Shibata T; Seto T; Takahashi T; Nakagawa K; Tanaka H; Takeda K; Nishio M; Mori K; Satouchi M; Hida T; Yoshimura N; Kozuki T; Imamura F; Kiura K; Okamoto H; Sawa T; Tamura T;
    Lancet Oncol; 2016 Aug; 17(8):1147-1157. PubMed ID: 27312053
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.
    Paz-Ares L; Dvorkin M; Chen Y; Reinmuth N; Hotta K; Trukhin D; Statsenko G; Hochmair MJ; Özgüroğlu M; Ji JH; Voitko O; Poltoratskiy A; Ponce S; Verderame F; Havel L; Bondarenko I; Kazarnowicz A; Losonczy G; Conev NV; Armstrong J; Byrne N; Shire N; Jiang H; Goldman JW;
    Lancet; 2019 Nov; 394(10212):1929-1939. PubMed ID: 31590988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cisplatin, ifosfamide, and prolonged oral etoposide in the treatment of patients with extensive small cell lung carcinoma.
    Glisson B; Lee JS; Palmer J; Fossella F; Shin DM; Murphy WK; Perez-Soler R; Hong WK
    Cancer; 1998 Jan; 82(2):301-8. PubMed ID: 9445186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase Ib dose-escalation study of everolimus combined with cisplatin and etoposide as first-line therapy in patients with extensive-stage small-cell lung cancer.
    Besse B; Heist RS; Papadmitrakopoulou VA; Camidge DR; Beck JT; Schmid P; Mulatero C; Miller N; Dimitrijevic S; Urva S; Pylvaenaeinen I; Petrovic K; Johnson BE
    Ann Oncol; 2014 Feb; 25(2):505-11. PubMed ID: 24368401
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cisplatin, Etoposide, and Bevacizumab Regimen Followed by Oral Etoposide and Bevacizumab Maintenance Treatment in Patients With Extensive-Stage Small Cell Lung Cancer: A Single-Institution Experience.
    Petrioli R; Roviello G; Laera L; Luzzi L; Paladini P; Ghiribelli C; Voltolini L; Martellucci I; Bianco V; Francini E
    Clin Lung Cancer; 2015 Nov; 16(6):e229-34. PubMed ID: 26072097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Weekly alternating therapy with irinotecan plus cisplatin and etoposide plus cisplatin in the treatment of patients with extensive small cell lung carcinoma.
    William WN; Uyeki J; Johnson FM; Feng L; Peeples BO; Fossella FV; Karp DD; Blumenschein GR; Stewart DJ; Glisson BS
    Cancer; 2010 May; 116(10):2409-15. PubMed ID: 20225329
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of a 3-day schedule with topotecan and cisplatin in patients with previously untreated small cell lung cancer and extensive disease.
    Sorensen M; Lassen U; Jensen PB; Østerlind K; Jeppesen N; Jensen BB; Mellemgaard A; Rytter C; Langer SW
    J Thorac Oncol; 2008 Aug; 3(8):902-6. PubMed ID: 18670309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I/II trial of gemcitabine plus cisplatin and etoposide in patients with small-cell lung cancer.
    De Marinis F; Migliorino MR; Paoluzzi L; Portalone L; Ariganello O; Cortesi E; Gamucci T; Gasperoni S; Cipri A; Martelli O; Nelli F;
    Lung Cancer; 2003 Mar; 39(3):331-8. PubMed ID: 12609572
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of cisplatin/etoposide and endostar for extensive-stage small-cell lung cancer.
    Zhou ZT; Zhou FX; Wei Q; Zou LY; Qin BF; Peng XS
    Cancer Chemother Pharmacol; 2011 Oct; 68(4):1027-32. PubMed ID: 21327933
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer.
    Cho BC; Dy GK; Govindan R; Kim DW; Pennell NA; Zalcman G; Besse B; Kim JH; Koca G; Rajagopalan P; Langer S; Ocker M; Nogai H; Barlesi F
    Lung Cancer; 2018 Sep; 123():14-21. PubMed ID: 30089585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III Randomized Trial of Ipilimumab Plus Etoposide and Platinum Versus Placebo Plus Etoposide and Platinum in Extensive-Stage Small-Cell Lung Cancer.
    Reck M; Luft A; Szczesna A; Havel L; Kim SW; Akerley W; Pietanza MC; Wu YL; Zielinski C; Thomas M; Felip E; Gold K; Horn L; Aerts J; Nakagawa K; Lorigan P; Pieters A; Kong Sanchez T; Fairchild J; Spigel D
    J Clin Oncol; 2016 Nov; 34(31):3740-3748. PubMed ID: 27458307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin, etoposide, and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma.
    Glisson BS; Kurie JM; Perez-Soler R; Fox NJ; Murphy WK; Fossella FV; Lee JS; Ross MB; Nyberg DA; Pisters KM; Shin DM; Hong WK
    J Clin Oncol; 1999 Aug; 17(8):2309-15. PubMed ID: 10561292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.
    Shimada M; Yamaguchi H; Fukuda M; Tomono H; Honda N; Dotsu Y; Taniguchi H; Gyotoku H; Senju H; Takemoto S; Ikeda T; Nakatomi K; Nakamura Y; Nagashima S; Yamazaki T; Mukae H
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):1059-1064. PubMed ID: 31486872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase I-II study of sequential administration of topotecan and oral etoposide (toposiomerase I and II inhibitors) in the treatment of patients with small cell lung carcinoma.
    Mok TS; Wong H; Zee B; Yu KH; Leung TW; Lee TW; Yim A; Chan AT; Yeo W; Chak K; Johnson P
    Cancer; 2002 Oct; 95(7):1511-9. PubMed ID: 12237920
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.